ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Mutated bacteria help metabolize phenylalanine

The synthetic strains developed by Synlogic could be used to treat people who can’t break down phenylalanine, found in proteins

by Tien Nguyen
August 19, 2018 | APPEARED IN VOLUME 96, ISSUE 33

 

09633-scicon11-scheme.jpg

People with phenylketonuria (PKU), a genetic disease characterized by a lack of the enzyme needed to break down the amino acid phenylalanine, are often hungry. Because phenylalanine can cause severe neurological damage if it builds up in the brain, people with PKU can’t consume much of the amino acid, which is found in meat, fish, milk, and eggs. While existing treatments can help some patients manage the disease—in combination with a restricted diet—they come with adverse side effects. Scientists at the company Synlogic hope to offer a new PKU therapy using genetically modified bacteria called SYNB1618, which is currently being evaluated in Phase I clinical trials. SYNB1618 is derived from a safe strain of bacteria called Escherichia coli Nissle that doesn’t colonize well in the gut. Researchers designed the bacteria to break down phenylalanine via two pathways (shown). In one pathway, phenylalanine ammonia lyase (PAL) converts phenylalanine to trans-cinnamate. In the other, l-amino acid deaminase (LAAD) produces phenylpyruvate. Synlogic researchers injected phenylalanine in mice missing the phenylalanine-metabolizing enzyme. The mice that were then administered SYNB1618 had 38% lower phenylalanine blood concentration than those that didn’t receive the treatment (Nat. Biotechnol. 2018, DOI: 10.1038/nbt.4222). The team also demonstrated SYNB1618’s ability to break down deuterium-labeled phenylalanine in monkeys, whose physical and kinetic digestion resembles humans’ more closely than the mouse digestion system does.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment